← Back to Search

Supportive Care for Young Adult Cancer Survivors

N/A

Waitlist Available

Led By K. Scott Baker

Research Sponsored by Fred Hutchinson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Received a therapeutic intervention (with curative intent if advanced stage disease) that included any of the following modalities: surgery, cytotoxic chemotherapy, biological or targeted agents, radiation therapy

Diagnosed with a first invasive malignancy of leukemia, lymphoma, melanoma, sarcoma, breast, thyroid, or colorectal cancer (stage 1-3 for solid tumors) between the ages of 15-39 years

Must not have

Diagnosed with a subsequent invasive malignancy other than non-melanoma skin cancer

Received hematopoietic stem cell transplant

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is studying how well an interactive survivorship program works in improving healthcare resources for adolescent and young adult cancer survivors.

Who is the study for?

This trial is for young adult cancer survivors aged 18 or older who were diagnosed with leukemia, lymphoma, melanoma, sarcoma, breast, thyroid, or colorectal cancer between ages 15-39. They must be within 1-5 years of diagnosis and have finished active treatment at least 6 months ago. Participants need to understand English and have access to email and a smartphone or internet.

What is being tested?

The INSPIRE-AYA study tests an interactive program designed to help adolescent and young adult cancer survivors by improving their access to healthcare resources. The goal is to enhance health literacy, self-management skills, adherence to care guidelines and reduce distress related to their past cancer experience.

What are the potential side effects?

Since this trial involves informational interventions rather than medical treatments or drugs, traditional side effects are not expected. However, participants may experience emotional discomfort when discussing their cancer experiences.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have undergone treatment for my advanced disease, including surgery, chemotherapy, targeted therapy, or radiation.

Select...

I was diagnosed with my first cancer between ages 15-39.

Select...

I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been diagnosed with a new cancer that is not non-melanoma skin cancer.

Select...

I have had a stem cell transplant.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in distress score from baseline to 12 months

Change in distress score from baseline to 3 months

Proportion of HCA-cancer surveillance (SM)

+1 more

Secondary study objectives

Proportion of healthcare adherence (HCA)-all

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm I (INSPIRE, telehealth care)Experimental Treatment4 Interventions

Patients receive a personalized SCP and use the INSPIRE mobile application. Patients may receive telehealth stepped care after 1 month.

Group II: Arm II (control website)Active Control2 Interventions

Patients receive access to a study-specific control website that has annotated links to existing resources for AYA survivors. After 12 months, patients receive a personalized SCP and have access to the digital INSPIRE intervention program without telehealth calls.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Supportive Care

2013

Completed Phase 2

~1710

0 / 5Eligibility criteria met